Jpmorgan Chase & CO Intra Cellular Therapies, Inc. Transaction History

Jpmorgan Chase & CO

$1.27 Trillion
Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 759,991 shares of ITCI stock, worth $100 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

759,991

Previous 5,126,092 85.17%

Holding current value

$100 Million

Previous $428 Million 76.58%

% of portfolio

0.01%

Previous 0.03%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 12, 2025	SELL	$81.78 - $131.92 $357 Million - $576 Million	-4,366,101 Reduced 85.17%	759,991 $100 Million
Q4 2024 Feb 12, 2025	SELL	$71.19 - $91.57 $11.4 Million - $14.7 Million	-160,193 Reduced 3.03%	5,126,092 $428 Million
Q3 2024 Dec 26, 2024	BUY	$67.99 - $80.84 $126 Million - $150 Million	1,851,053 Added 53.88%	5,286,285 $387 Million
Q3 2024 Nov 08, 2024	BUY	$67.99 - $80.84 $126 Million - $150 Million	1,851,053 Added 53.88%	5,286,285 $387 Million
Q2 2024 Dec 26, 2024	SELL	$64.76 - $79.84 $120 Million - $148 Million	-1,851,053 Reduced 35.02%	3,435,232 $235 Million
Q2 2024 Aug 12, 2024	BUY	$64.76 - $79.84 $109 Million - $134 Million	1,679,284 Added 95.63%	3,435,232 $235 Million
Q1 2024 Dec 26, 2024	SELL	$64.37 - $75.65 $227 Million - $267 Million	-3,530,337 Reduced 66.78%	1,755,948 $122 Million
Q1 2024 May 10, 2024	SELL	$64.37 - $75.65 $20.4 Million - $24 Million	-316,667 Reduced 15.28%	1,755,948 $122 Million
Q4 2023 Dec 26, 2024	SELL	$46.37 - $73.65 $149 Million - $237 Million	-3,213,670 Reduced 60.79%	2,072,615 $148 Million
Q4 2023 Feb 12, 2024	BUY	$46.37 - $73.65 $408,658 - $649,077	8,813 Added 0.43%	2,072,615 $148 Million
Q3 2023 Nov 14, 2023	BUY	$52.09 - $64.1 $4.5 Million - $5.54 Million	86,388 Added 4.37%	2,063,802 $108 Million
Q2 2023 Aug 11, 2023	BUY	$54.67 - $66.44 $8.01 Million - $9.74 Million	146,530 Added 8.0%	1,977,414 $125 Million
Q1 2023 May 18, 2023	BUY	$43.8 - $56.99 $5.23 Million - $6.8 Million	119,387 Added 6.98%	1,830,884 $99.1 Million
Q1 2023 May 11, 2023	BUY	$43.8 - $56.99 $9.35 Million - $12.2 Million	213,583 Added 14.26%	1,711,497 $92.7 Million
Q4 2022 Feb 13, 2023	BUY	$44.07 - $54.45 $57.7 Million - $71.3 Million	1,310,130 Added 697.68%	1,497,914 $79.3 Million
Q3 2022 Nov 14, 2022	SELL	$42.7 - $59.99 $61,189 - $85,965	-1,433 Reduced 0.76%	187,784 $8.74 Million
Q2 2022 Aug 11, 2022	BUY	$43.0 - $65.64 $1.38 Million - $2.11 Million	32,073 Added 20.41%	189,217 $10.8 Million
Q1 2022 May 11, 2022	BUY	$38.74 - $62.09 $637,427 - $1.02 Million	16,454 Added 11.7%	157,144 $9.62 Million
Q4 2021 Feb 10, 2022	SELL	$35.2 - $53.42 $46,217 - $70,140	-1,313 Reduced 0.92%	140,690 $7.36 Million
Q3 2021 Nov 12, 2021	BUY	$28.72 - $42.49 $4.08 Million - $6.03 Million	142,003 New	142,003 $5.29 Million

Others Institutions Holding ITCI

# of Institutions

449

Shares Held

93.4M

Call Options Held

2.24M

Put Options Held

1.86M

View Full List

About Intra-Cellular Therapies, Inc.

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $12.4B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

More about ITCI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Intra Cellular Therapies, Inc. Transaction History